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stratiﬁed by the stage of disease. RESULTS: Annual outpatient costs per patient were 
694; 877; and US$1409 for Qingdao, Nanjing, and Beijing, respectively. Among out-
patient expenses, western medications formed the bulk of these costs in Qingdao 
(58.9%) and Beijing (62.9%), but a lesser amount in Nanjing (46.9%). The use of 
antivirals is 20% in Nanjing and 37% in Qingdao of total western medications. TCM 
prescriptions for CHB varied across these different cities with the greatest usage in 
Nanjing (20.8%). For hospitalized patients, annual costs per patient were 1893; 2101, 
and US$2622 in Nanjing, Qingdao, and Beijing, respectively. The costs increased 
progressively in patients with compensated liver disease, (US$1983) decompensated 
liver disease (US$2802) and hepatocellular cancer (US$3019), respectively. Patients 
contributed around 50% towards outpatient costs and 30% towards inpatient care. 
CONCLUSIONS: CHB exerts a signiﬁcant health and ﬁnancial burden which progres-
sively increases as patients progress from early to late stages of the disease. While 
antivirals are associated with a reduction in disease progression, their use remains 
relatively low in urban areas in China. Further work is required to determine whether 
an early treatment with effective CHB medications can reduce the overall ﬁnancial 
burden within China.
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OBJECTIVES: Outbreaks of inﬂuenza often incur a substantial burden in terms of 
health care utilization, health care costs and societal costs. The aim of this analysis 
was to identify gaps in available data related to the economic burden of inﬂuenza in 
children in the UK, Germany, Italy, Spain, France, Sweden, The Netherlands, Finland, 
and Austria. METHODS: A structured literature search (1970-March 2009) involving 
PubMed, EMBASE, and the Cochrane Library formed the basis of the gap analysis. 
Articles were excluded if not related to inﬂuenza and not reporting resource use, cost, 
absenteeism or utility data in a country of interest for a group a18 years. A total of 
171 articles were short-listed for full-text review, and data extracted from 43. 
RESULTS: Available published data suggests a signiﬁcant burden of inﬂuenza in chil-
dren. Most studies reporting health care utilization (31 of 32) focused on hospitaliza-
tion, clinician visits, and prescription of antibiotics, antipyretics, or analgesics. 
Regarding cost burden of inﬂuenza, the number of studies speciﬁcally related to the 
pediatric population was small, and rarely included a breakdown by age group and 
disease severity. Absenteeism data focused on missed days at day care/school or 
parental lost work days. Little information was reported on household contacts or on 
reductions in productivity. Studies reporting impact on quality of life were very 
limited. Burden information is fragmented and incomplete. Only for Italy, France, and 
Spain are data available from multiple studies speciﬁc to a pediatric cohort. CONCLU-
SIONS: Existing information suggests a signiﬁcant burden of inﬂuenza in children. 
Burden information across reviewed EU countries is incomplete and fragmented. A 
multinational data collection initiative providing a complete and age-stratiﬁed picture 
of the burden of inﬂuenza in children appears warranted.
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OBJECTIVES: Anti-venom is the only speciﬁc treatment to prevent neurological dis-
orders, amputation and death in snakebite envenoming, categorized as neglected 
tropical disease by WHO. Majority of victims are young and economically productive. 
Hence, the economic impact of their disability is considerable. We reviewed the burden 
and cost of snakebite envenoming: its incidence, morbidity and mortality rates, and 
the access to anti-venom treatment. METHODS: The information was retrieved from 
1985–2009 from MEDLINE, Google Scholar and WHO website with search terms 
including “snakebite”, “antivenom”, “cost of antivenom” and “snakebite morbidity 
and mortality”. RESULTS: Snakebite as a tropical disease causes considerable morbid-
ity and mortality worldwide with global annual estimates for 2007 ranging from 
1,200,000–5,500,000 for snakebite incidence to 42,1000–1,841,000 and 20,000–
94,000 for envenoming and deaths respectively. South Asia (121,000) has the highest 
number of envenoming followed by Southeast Asia (111,000) and east-Sub-Saharan 
Africa (43,000). The price of anti-venom has typically risen by 10 fold over the last 
20 years. For example, the costs to Australian hospitals of CSL polyvalent and taipan 
antivenoms were A$1833 and A$1577 in 2003 as compared to A$300 and A$245 in 
1985, respectively. The number of anti-venom vials increases with severity (upto 5, 
10 and 20 for mild, moderate and severe cases respectively) thereby increasing cost 
of treatment. Inadequate anti-venom supply further exaggerates this problem as the 
current annual need amounts to 10,000,000 vials. Incidence is higher in rural areas, 
where incomes are generally lower. In Nepal, out-of-pocket expenses (US$69) equal 
several months of income as most people have a daily incomes of 1–2 US$, besides 
15 days of working incapacity period. CONCLUSIONS: The excessive cost and 
inadequate supply of anti-venom renders it inaccessible to most people in developing 
countries. Appropriate measures should be taken to prevent the clinical and economic 
impact of this neglected disease.
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OBJECTIVES: Despite a signiﬁcant decrease over the last 20 years, the prevalence of 
hepatitis B remains high in Portugal (an estimated 36,000 cases in 2002). Hepatitis B 
represents a relevant public health issue due to its dramatic consequences when it turns 
chronic, namely the associated risk of cirrhosis and hepatocellular carcinoma. The aim 
of this study was to estimate annual cost of disease states associated with chronic 
hepatitis B (CHB) from the perspective of Portuguese NHS. METHODS: We estimated 
the resource use to treat CHB and its disease states, namely Compensated Cirrhosis 
(CC), Decompensated Cirrhosis (DC), Hepatocellular Carcinoma (HCC) and Liver 
Transplantation follow-up (LT).A panel of 8 specialists from Portuguese NHS hospi-
tals were surveyed using a modiﬁed Delphi technique. Data were collected for outpa-
tient visits, laboratory tests, diagnostic and therapeutic procedures, drugs (excluding 
antivirals) and hospitalisations. RESULTS: The resource use for all categories increases 
with severity of disease. Estimated average annual costs are a1,125 for CHB, a1,761 
for CC, a18,278 for DC and a26,388 for HCC. Cost for LT procedure within Portu-
guese DRG is estimated at a100,785, while average post-LT costs are estimated at 
a30,540 and a24,780 for the ﬁrst and subsequent years, respectively. Costs for CHB 
and CC are mainly due to outpatient visits and serology tests. By contrast, inpatient 
days are the main driver of costs for DC (79%), HCC (50%) and post-LT in the ﬁrst 
year after treatment (71%). Drugs represent the second major component of costs for 
HCC (18%), and post-LT in the ﬁrst (23%) and second (72%) year, related to immu-
nosuppressants and hepatitis B immunoglobulin respectively. CONCLUSIONS: Our 
study shows that annual costs of managing CHB disease states are high and increase 
substantially with disease severity. Both economic arguments and public health ones 
point to the necessity to control CHB infection and its progression.
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OBJECTIVES: Poor adherence is a serious issue in the management of patients with 
chronic hepatitis C (CHC) owing to the difﬁculty of treatment with pegylated inter-
feron/ribavirin (Peg-IFN/RBV). Future small molecule treatments may obviate difﬁcul-
ties of Peg-IFN/RBV therapy. We analyzed cohorts of CHC patients treated with 
Peg-IFN/RBV to quantify the impact of medication adherence on health care costs 
over 4 years follow-up. METHODS: A retrospective claims analysis was performed 
from January 1, 2001 through December 31, 2007 using the Medstat MarketScan 
database. Inclusion criteria: 1) CHC patients greater than 18 years; 2) who initiated 
Peg-IFN/RBV treatment in 2002 (index); and 3) continued for greater than 24 weeks 
from index. Continuous enrollment from 6 months prior to index (baseline) to 48 
weeks after index (follow-up) was required. Patients were excluded if they had a 
diagnosis of HIV or HBV. Adherence was deﬁned by medication possession ratio 
(MPR), days with Peg-IFN/RBV divided by 336 days or 48 weeks. Overall Medical 
and Pharmacy costs were compared between adherent (MPR q 80%) versus non-
adherent patients (MPR  80%), controlling for age, gender and baseline costs. 
RESULTS: A total of 1173 patients met study inclusion criteria (adherent, n  319; 
non-adherent, n  854). The majority of patients were male (64.5%); the mean age 
was 47 years. Univariate analysis revealed that Overall Medical, ER, Inpatient and 
Outpatient Hospitalizations, and Pharmacy costs were signiﬁcantly greater (P a 0.05) 
in non-adherent compared to adherent patients. Multivariate analysis conﬁrmed these 
results (difference in mean; 95% CI) for Overall Medical ($10,006; 1530–18,482) and 
Outpatient Hospitalization ($3,024; 553–5,494) costs. CONCLUSIONS: Medication 
non-adherence to Peg-IFN/RBV treatment was associated with greater health care 
costs. These results may be due to decreased Sustained Viral Response associated with 
low adherence. Treatment with future small molecules may potentially improve adher-
ence and reduce costs.
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OBJECTIVES: To quantify and compare the impact of using different methods for 
measuring indirect cost on the total disease cost in the economic assessment of 7-valent 
pneumococcal conjugate vaccines (PCV-7) versus pneumococcal non-typeable Hae-
mophilus inﬂuenzae protein-D conjugate vaccine (PHiD-CV) in Germany.   METHODS: 
Five different ways of using the human capital (HCM) and friction cost method (FCM) 
for estimating indirect cost have been incorporated into an age-compartmental, one-
year cross-sectional, vaccine steady-state, population-based model assessing the 
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 economic beneﬁt between two different pneumococcal vaccines. Indirect costs were 
estimated for both vaccines according to the ﬁve approaches to assess the methodologi-
cal inﬂuence on the total disease cost difference between PCV-7 and PHiD-CV. Base-
line indirect cost estimates include the cost of productivity losses of paid workers due 
to disease, sequelae, and earlier death. Some of the approaches include in terms of 
cost: children’s future productivity losses, unpaid work loss and parents’ work loss, 
when looking after their sick children. RESULTS: Compared to FCM, HCM based 
approaches constantly generated higher estimates of indirect cost. Results of HCM 
ranged between a1.1bn (PHiD-CV), a1.2bn (PCV-7) and a1.9bn (both vaccines), while 
for FCM they ranged between a0.2bn and a0.9bna (both vaccines). Cost attributed 
to earlier death varied with a factor of 35; indirect cost due to earlier death as a pro-
portion of total indirect cost varied between 16% (conservative FCM) and 79% 
(conservative HCM). The overall impact on total disease cost differences between the 
two vaccines did not alter with any approach selected (PHiD-CV always dominates 
PCV-7), but the amount of savings signiﬁcantly differs depending on the used method. 
CONCLUSIONS: Although different approaches for estimating indirect cost have 
a huge impact on the cost difference between pneumococcal conjugate vaccines in  
Germany, the rating of these vaccines (PCV-7 dominated by PHiD-CV) stays unaf-          
fected. FCM always generates lower estimates than HCM.
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OBJECTIVES: To evaluate the clinical and economic impact of bacteremia caused by 
extended-spectrum beta-lactamases (ESBL) producing Escherichia coli. METHODS: 
A case-control study was conducted in a teaching hospital in Hong Kong. Case 
patients who had blood cultures positive for ESBL-producing E. coli were matched 
with patients who had bacteremia caused by non-ESBL-producing E. coli from 
January 2002 through December 2004. Demographic data, clinical factors and health 
care resource utilization for bacteremia were retrieved from medical records. Outcome 
measurements included mortality, infection-related cost and infection-related length 
of stay. RESULTS: Thirty-ﬁve case patients with ESBL-producing E. coli bacteremia 
were matched with 35 control patients with non-ESBL-producing E. coli bacteremia. 
The mortality rates were 8/35 (22.9%) in cases and 1/35 (2.9%) in controls. The 
average total cost for cases and controls were HK$51,100 o $44,292 and HK$30,300 
o $19,427 (USD1  HKD7.8), respectively. Mean infection-related length of stay in 
cases was 11.5 o 4.9 days and 8.4 o 5.2 days in controls. Multiple regression analysis 
showed that ESBL production was not signiﬁcantly associated with mortality, but it 
was a signiﬁcant predictor of infection-related cost (ME: 1.32; 95% CI  1.04–1.69; 
P  0.001) and infection-related length of stay (ME:1.42, 95% CI  1.16–1.73, P  
0.001). CONCLUSIONS: ESBL-production was associated with increased length of 
stay and direct medical cost for treatment of E. coli bacteremia.
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OBJECTIVES: Published clinical trials have shown similar clinical cure rates and 
shorter length of stay (LOS) for linezolid compared to vancomycin and teicoplanin in 
patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. The aim 
of this pharmacoeconomic evaluation was to assess the cost-effectiveness of linezolid 
vs. vancomycin and teicoplanin from the perspective of Czech health care system. 
METHODS: We have collected the data on health care resource utilisation in patients 
with MRSA infections treated with linezolid, vancomycin or teicoplanin (drug admin-
istration, monitoring, hospitalisations, adverse events). Costs from ofﬁcial price lists 
of health insurance companies were applied to all colected items. Total costs of line-
zolid, vancomycin and teicoplanin treatment course were compared. We have analysed 
two subsets of patients—with MRSA infections after surgery hospitalized in ortho-
paedic clinic and patients with complicated MRSA infection requiring intensive care. 
RESULTS: Total number of 74 patients was analysed according to resource use and 
costs. The mean length of stay in MRSA patients in ortopaedic surgery patients was 
36.7 days and the mean hospitalisation cost was 94,462 CZK (a3,633). The mean 
length of stay in MRSA intesive care patients was 45.2 days and the mean hospitalisa-
tion cost was 204,775 CZK (a7876). There was a tendency for shorter length of hos-
pitalisation in the group of linezolid patiens in comparison to teicoplanin patients 
(32.7 vs. 43.6 days). The increased antibiotic acquisition cost of linezolid (three time 
higher in comparison with vancomycin and two times higher in comparison with tei-
coplanin) was balanced by the estimated cost savings for hospitalisations, and addi-
tional savings in laboratory monitoring, concomitant medication and adverse events. 
CONCLUSIONS: Based on the patient-speciﬁc data linezolid is cost-effective option 
for hospitalised MRSA patients in Czech Republic. Despite higher acquisition cost the 
total hospitalisation costs are very similar to teicoplanin and vancomycin.
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OBJECTIVES: Compare the economic impact of prophylaxis with valganciclovir 
against cytomegalovirus (CMV) infection versus non-prophylactic decision, in renal 
transplantation recipients, for analysing cost of treatment. METHODS: Economic 
evaluation through a theoretical cost analysis to assess the impact of using prophylaxis 
with valganciclovir (450 mg every 12 h for 100 days) compared with no prophylaxis, 
in patients receiving a renal transplantation with high (D/R-) and intermediate (R) 
risk of CMV disease. Outcomes evaluated were secondary morbidity due to CMV 
infection, including organ rejection. Calculations about the referred complications 
were based on informed frequencies from medical literature. Costs were evaluated 
from the service provider perspective, in US dollars and include the resources used for 
prophylaxis and complications. Cost analysis results from the difference between 
symptomatic disease due to CMV, the cost of treating an acute rejection and the 
ﬁnancial pressure regarding both situations. The number of patients needed to treat 
(NPT) for achieving clinical success was calculated. RESULTS: Based on a hypotheti-
cal scenario of 1 thousand patients, equally distributed in each group, the frequency 
of symptomatic infection in the valganciclovir group would be 1% against to 31% in 
the non-prophylaxis group. The same tendency is kept regarding development of 
asymptomatic infection (4% vs. 32%) as well as organ rejection (1.5% vs 16.1%). 
CONCLUSIONS: With this theoretical pharmacoeconomic evaluation it is demon-
strated that the use of prophylaxis with valganciclovir might be a cost-saving alterna-
tive for a medium-term perspective, derived from reduction in the frequency of 
infections and indirect events related with CMV replication like organ rejection. In 
patients with intermediate risk (R), a comparison must be established between costs 
of prophylaxis and pre-emptive intervention, because the last might reduce medica-
tions consumption but increasing diagnosis and monitoring costs, as well as not 
avoiding indirect events related to viral replication.
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OBJECTIVES: The aim of this study is to calculate direct cost of management diabetic 
foot infection (DFI) due to MRSA in diabetes mellitus (DM) patient-population treated 
with linezolid and to identify the most important factors related to treatment costs. 
METHODS: A cost-study was performed with data from 70 prospectively patients 
with DFI treated with linezolid from-2006-to-2008 in 10 Spanish Hospitals included 
in a non-comparative clinical trial. Cost for in-patient-stay, and outpatient manage-
ment were calculated retrospectively from diagnosis until healing or death in those 
patients where the cost data could be estimated. Cost for linezolid treatment (IV-oral), 
IV administration and monitoring were also estimated. Resource utilization not col-
lected during the study was based on published literature. Cost data derived from lit-
erature and Spanish database. Mean values for each item were used to calculate cost 
average. All costs are expressed in Euros 2007. RESULTS: Mean age was 63.2 years 
old (SD 13.0), being 68.1% males. Duration of DM was 16.5 years. A total of 55 
patients healed without amputation (78.6%) and 9 (12.9%) healed after amputation. 
Total cost for a patient without amputation was a9429.7 (95% CI 8404.2–10455.3), 
while corresponding cost for a patient with amputation was a9949.9 (95% CI 6034.3–
13865.6). Hospitalization accounts for 54% of cost of treating DFI in patients without 
amputation and 48% in patients with amputation. Surgery cost was 17% of total cost 
in patients undergoing amputation. Drug costs didn’t account for the major part of 
costs incurred during in-patient phase. Outpatient costs were 5% and 7% of total cost 
in patients without and with amputation, respectively. CONCLUSIONS: These are 
the ﬁrst cost data results for DFI due to MRSA in Spain. Amputations were associated 
with high cost mainly due to surgery and long-term cost. These ﬁndings suggest the 
potential efﬁciency of a targeted approach program to prevent amputations in patients 
with DFI.
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OBJECTIVES: Whether combination antiviral therapy is cost-effective for patient with 
HCV in the real-world setting has not yet to be shown. This study is to compare the 
cost-effectiveness of combination antiviral therapy with no treatment in cirrhotic 
patients with q1 doses of combination prescriptions (base case), and with q48 weeks 
